Release Date: June 30, 2025
Expiration Date: June 30, 2026
Activity Overview
Cardiometabolic disorders are a significant source of morbidity and mortality in psoriatic disease. The presence of traditional cardiovascular (CV) risk factors, such as hypercholesterolemia, metabolic syndrome, and obesity, contributes to the elevated risk of CV disease in patients with psoriasis. CV risk stratification and management should be integral to patient care, yet 20% to 40% of psoriasis patients with CV risk factors remain untreated, often due to a lack of awareness or time constraints.
This online educational activity is designed to provide expert perspectives of new and emerging data from clinical trials in patients with cardiovascular complications of psoriasis with a focus on reviewing the safety data from recent clinical trials and how to apply this data in practice. The program includes a case-based approach to highlight the key messages shared by the expert faculty.
Target Audience
This educational activity is directed toward dermatologists. Cardiologists, internists, NPs, PAs, RNs, and other HCPs involved in the care of patients with PsO and CV comorbidities will also find it useful.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the impact of cardiovascular comorbidities in patients with psoriasis and their influence on overall disease management.
- Evaluate the efficacy and safety of biologic therapies in psoriasis management, including their impact on cardiovascular risk.
- Implement holistic management plans in patients with psoriasis that address cardiovascular risk.
Lourdes M. Perez-Chada MD, MMSc
Instructor in Dermatology
Harvard Medical School
Clinical Researcher
Department of Dermatology
Mass General Brigham
Boston, MA
Disclosures: Advisory Board; Takeda, BMS, IDEOM; Other: Honoraria Recipient; Takeda, BMS, IDEOM
Brittany Weber MD, PhD, FACC, FAHA
Director, Cardio-Dermatology and Cardio-Rheumatology Program
Assistant Professor of Medicine
Assistant Professor of Dermatology
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosures: Consultant; Oruka, Novo Nordisk, Kiniksa, and BMS
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
